The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor

Clinical Drug Investigation

Volumn 33, Issue 7, 2013, Pages 489-496

  Zhang, Wenhui ^a   Krauwinkel, Walter J J ^b   Keirns, James ^a   Townsend, Robert W ^a   Lasseter, Kenneth C ^c   Plumb, Lisa ^a   Kadokura, Takeshi ^d   Ushigome, Fumihiko ^d   Smulders, Ronald ^b  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^b Astellas Pharma Global Development   (Netherlands)

^c Clinical Pharmacology of Miami Inc   (United States)

^d ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; IPRAGLIFLOZIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG URINE LEVEL; EPISTASIS; FEMALE; HEADACHE; HUMAN; HYPOGLYCEMIA; LIVER DYSFUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE;

FEMALE; GLUCOSIDES; HUMANS; LIVER; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84879824420     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0089-6     Document Type: Article

References (18)

1. Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med. 2012;44:375-93.
2. Neumiller JJ, White JR Jr, Campbell RK. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70:377-85.
3. Wright EM. Renal Na(+)-glucose co-transporters. Am J Physiol Renal Physiol. 2001;280:F10-8.
4. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495-502.
5. Kadokura T, Saito M, Utsuno A, et al. Ipragliflozin (ASP1941), a selective sodium-dependent glucose cotransporter 2 inhibitor, safely stimulates urinary glucose excretion without inducing hypoglycemia in healthy Japanese subjects. Diabetol Int. 2011;2:172-82. doi: 10.1007/s13340-011-0037-8.
6. Veltkamp SA, Kadokura T, Krauwinkel WJ, et al. Effect of ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig. 2011;31:839-51.
7. Schwartz SL, Akinlade B, Klasen S, et al. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13:1219-27.
8. Fujita E, Ushigome F, Suzuki K, et al. Characterization and identification of in vivo and in vitro metabolites of ipragliflozin. Poster W4408 presented at 25th American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition; 2-5 Mar 2011; Washington, DC. http://www.aapsj.org/abstracts/AM-2011/W4408.pdf.
9. Ushigome F, Kasai Y, Uehara S, et al. Identification of UDP-glucuronosyltransferase (UGT) isozymes involved in ipragliflozin metabolism in human liver. Poster W4421 presented at 25th American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition; 2-5 Mar 2011; Washington, DC. http://www.aapsj.org/abstracts/AM-2011/W4421.pdf.
10. Tolman KG, Fonseca V, Dalpiaz A, et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30:734-43.
11. Wilding JP, Ferrannini E, Fonseca VA, et al. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab 2012. doi: 10.1111/dom.12038.
12. Fonseca VA, Ferrannini E, Wilding JP, et al. Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complicat. 2012. doi: 10.1016/j.jdiacomp.2012.11.005.
13. Debinski HS, Lee CS, Danks JA, et al. Localization of uridine 5′-diphosphate-glucuronosyltransferase in human liver injury. Gastroenterology. 1995;108:1464-9.
14. Congiu M, Mashford ML, Slavin JL, et al. UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos. 2002;30:129-34.
15. Dostalek M, Court MH, Hazarika S, et al. Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011;39:448-55.
16. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147-61.
17. Data on file: Brooks A, Absolute bioavailability study. Astellas Pharma Europe BV, 2011.
18. Kasichayanula S, Liu X, Zhang W, et al. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther. 2011;33:1798-808.